Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...
The FDA has cleared the first tubeless automated insulin delivery system with a smartphone app control. The FDA has cleared Insulet’s Omnipod 5 automated insulin delivery system, marking the first ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted ...
Q4 2025 Management View Ashley McEvoy, CEO, reported "we closed 2025 with another strong quarter, recording our 10th consecutive year of 20% or greater constant currency revenue growth," citing ...
Insulet PODD is well-poised to grow in the coming quarters due to the strength of its Omnipod 5 platform. The company is strongly executing against its long-term priorities to drive penetration, ...
Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.
As Americans flock to nearby orchards for festive bouts of autumn apple picking, Insulet is celebrating a particularly bountiful stateside Apple harvest itself. The diabetes devicemaker has earned FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results